Navigation Links
Erythromycin A produced in E. coli for first time
Date:11/24/2010

MEDFORD/SOMERVILLE, Mass. -- Researchers at Tufts University School of Engineering have reported the first successful production of the antibiotic erythromycin A, and two variations, using E. coli as the production host.

The work, published in the November 24, 2010, issue of Chemistry and Biology, offers a more cost-effective way to make both erythromycin A and new drugs that will combat the growing incidence of antibiotic resistant pathogens. Equally important, the E. coli production platform offers numerous next-generation engineering opportunities for other natural products with complex biosynthetic pathways.

"We have now established E. coli as a viable option for making erythromycin A and as a platform for the directed production of erythromycin analogs. Our ability to fully manipulate erythromycin A's biosynthetic pathway to expand molecular diversity and antibiotic activity help sets a precedent for producing other similarly complex and medicinally relevant natural products," said lead researcher Blaine Pfeifer, Ph.D., assistant professor of chemical and biological engineering at Tufts.

Erythromycin A is a potent weapon in the treatment of bacterial infections. The bacterium Saccharopolyspora erythraea, which is found in the soil, naturally produces several variants of erythromycin. Erythromycin A is the most common and most biologically active.

Because of the challenges associated with engineering Saccharopolyspora erythraea, researchers have hoped to achieve the complete production of erythromycin A using E. coli. More than 20 enzymes must work in concert to create the erythromycin A molecule. This genetic and biochemical complexity makes synthesis notoriously hard. Previous research had reported manufacture of erythromycin A intermediates in E. coli but not the final product.

"To transfer and reconstitute these biosynthetic pathways is very difficult. In fact, erythromycin A poses nearly every challenge that must be addressed in the quest for complex heterologous biosynthesis of natural products," Pfeifer said.

He noted that the Tufts researchers followed a direction that was different from other groups. The Tufts team focused on reconstituting and ultimately manipulating the compound's original biosynthetic pathway rather than using analogous enzymes extracted from analogous pathways. The research team included Haoran Zhang, doctoral student in chemical engineering; Yong Wang, former postdoctoral associate now at East China University of Science & Technology; Jiequn Wu, a visiting doctoral student from East China University of Science & Technology, and Karin Skalina, a Tufts senior who is studying chemical engineering.


'/>"/>

Contact: Kim Thurler
kim.thurler@tufts.edu
617-627-3175
Tufts University
Source:Eurekalert

Related biology technology :

1. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
2. Martek to be the Sole Source Supplier of DHA and ARA for Infant Formulas Produced By Grupo Ricap
3. SemBioSys begins phase I/II trial of insulin produced in plant seeds
4. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
5. Semiconducting nanotubes produced in quantity at Duke
6. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
7. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
8. Inaugural Pharma Exchange Conference Produced by Informex to Draw Together Milwaukee, Wisconsin Chemical Industry
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
10. MEDRAD Installs First Intego(TM) PET Infusion System
11. Pioneering IVF Technique Produces Region's First Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
Breaking Biology News(10 mins):